CATX
Perspective Therapeutics, Inc.
$3.03
-6.77%
$370.7M
No data for this timeframe.
Vol
Market Cap$370.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders8 funds
Inst. Value$29.8M
Inst. Activity4 buys / 2 sells
SEC Reports3
Press Releases8
Recent Activity
Jun 5, 2026
SEC
Perspective Therapeutics updated its corporate presentation on June 1, 2026, highlighting ASCO 2026 data for its 212Pb-b
8-K — Impact 3/10
Jun 4, 2026
short_volume
Short Volume: CATX — 58.9% short (1.0M / 1.7M)
Short: 996,517 | Exempt: 13,513 | TRF Vol: 1,690,971 | Short Ratio: 58.9% | Off-exchange volume (dar
May 11, 2026
SEC
Perspective Therapeutics reported Q1 2026 results with a net loss of $26.2M ($0.25/share), widening from $18.2M loss in
8-K — Impact 4/10
May 4, 2026
SEC
Perspective Therapeutics filed an 8-K reporting that it posted a presentation with estimated cash, cash equivalents, and
8-K — Impact 2/10
Mar 2, 2026
Insider
Martinez Maria E sold 50,000 shares
Director @ $0.00 ($0.00)
Mar 2, 2026
Insider
Morich Frank sold 50,000 shares
Director @ $0.00 ($0.00)
Mar 2, 2026
Insider
Williamson Robert F III sold 50,000 shares
Director @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
4,474,522 shares ($12.3M)
Price Targets
$12.93
+326.8% upside
Strong Buy
Current $3.03
Low $6.00
Median $13.00
High $18.00
15 analysts
$6.00
$18.00
Analyst Ratings
4Strong Buy
14Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Apr 20, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | UBS | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▼ -2.8% | $-0.45 — $-0.23 | 7% YoY | 10 |
| Next Q | $-0.30 ▼ -5.4% | $-0.52 — $-0.23 | 15% YoY | 10 |
| Current FY | $-1.16 ▲ +8.7% | $-1.37 — $-0.96 | 18% YoY | 8 |
| Next FY | $-1.15 ▲ +1.8% | $-1.39 — $-0.90 | 0% YoY | 6 |
Latest Reports
NEUTRAL
8-K
3/10
Perspective Therapeutics updated its corporate presentation on June 1, 2026, highlighting ASCO 2026 data for its 212Pb-b
Jun 5, 2026
NEUTRAL
Press
5/10
Perspective Therapeutics announced the first patient dosed with [212Pb]VMT-α-NET in a new meningioma cohort of its ongoi
Jun 3, 2026
NEUTRAL
8-K
4/10
Perspective Therapeutics reported Q1 2026 results with a net loss of $26.2M ($0.25/share), widening from $18.2M loss in
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $12.3M | ADD |
| VANGUARD GROUP INC | $9.6M | — |
| TWO SIGMA INVESTMENTS, LP | $3.3M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.5M | NEW |
| BANK OF AMERICA CORP | $1.2M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 2, 2026 | Martinez Maria | A | $0.00 |
| Mar 2, 2026 | Morich Frank | A | $0.00 |
| Mar 2, 2026 | Williamson Robert | A | $0.00 |
| Mar 2, 2026 | HENSON HEIDI | A | $0.00 |
| Mar 2, 2026 | Hunt Jonathan | A | $0.00 |
8 institutional holders with $29.8M total value (10,850,188 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, TWO. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 4,474,522 | $12.3M | 41.2% | ADD +62.1% |
| 2 | VANGUARD GROUP INC | 3,490,658 | $9.6M | 32.2% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,198,644 | $3.3M | 11.0% | DOUBLED +130.7% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 535,477 | $1.5M | 4.9% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 424,519 | $1.2M | 3.9% | TRIM -46.0% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 352,493 | $969.4K | 3.2% | NEW |
| 7 | FMR LLC | 307,055 | $844.4K | 2.8% | NEAR_EXIT -96.9% |
| 8 | WELLS FARGO & COMPANY/MN | 66,820 | $183.8K | 0.6% | ADD +46.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 2,760,861 | 4,474,522 | +62.1% | $12.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 519,668 | 1,198,644 | +130.7% | $3.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 785,823 | 424,519 | -46.0% | $1.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 352,493 | — | $969.4K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 10,010,865 | 307,055 | -96.9% | $844.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 45,695 | 66,820 | +46.2% | $183.8K | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,623,388 | 2,760,861 | +70.1% | $9.5M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 327,500 | 785,823 | +139.9% | $2.7M | 2025-Q3 |
| UBS Group AG | ADD | 372,710 | 641,143 | +72.0% | $2.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 27,059 | 38,243 | +41.3% | $131.6K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 163,460 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,143,462 | 1,558,451 | +36.3% | $3.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 286,178 | 530,288 | +85.3% | $1.1M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 163,460 | — | $348.2K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 285,401 | 1,143,462 | +300.7% | $3.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 86,386 | 571,748 | +561.9% | $1.8M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 16,824 | 286,178 | +1601.0% | $912.9K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 18,168 | 26,462 | +45.7% | $84.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 433,522 | — | $5.8M | 2024-Q3 |
| MORGAN STANLEY | ADD | 151,896 | 285,401 | +87.9% | $3.8M | 2024-Q3 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Martinez Maria E | Director | A | 50,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Morich Frank | Director | A | 50,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Williamson Robert F III | Director | A | 50,000 | $0.00 | $0.00 |
| Mar 2, 2026 | HENSON HEIDI | Director | A | 50,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Hunt Jonathan Robert | Chief Accounting Officer | A | 90,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Spoor Johan M. | Chief Executive Officer | A | 735,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Puhlmann Markus | Chief Medical Officer | A | 150,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Woods Lori A | Director | A | 50,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.0/10.
NEUTRAL
8-K
3/10
Perspective Therapeutics updated its corporate presentation on June 1, 2026, highlighting ASCO 2026
Jun 5, 2026
NEUTRAL
8-K
4/10
Perspective Therapeutics reported Q1 2026 results with a net loss of $26.2M ($0.25/share), widening
May 11, 2026
NEUTRAL
8-K
2/10
Perspective Therapeutics filed an 8-K reporting that it posted a presentation with estimated cash, c
May 4, 2026
NEUTRAL
5/10
Perspective Therapeutics announced the first patient dosed with [212Pb]VMT-α-NET in a new meningioma
Jun 3, 2026
NEUTRAL
4/10
Perspective Therapeutics announced it will present updated data on three clinical-stage programs ([²
May 21, 2026
NEUTRAL
3/10
Perspective Therapeutics announced first patient dosing in two new cohorts of its Phase 1/2a trials
May 18, 2026
NEUTRAL
3/10
Perspective Therapeutics announced upcoming corporate updates in May 2026, including an analyst even
Apr 24, 2026
BULLISH
7/10
Perspective Therapeutics announced updated interim results from its Phase 1/2a trial of [212Pb]VMT-α
Apr 20, 2026
NEUTRAL
2/10
Perspective Therapeutics announced upcoming investor presentations at two biopharma conferences in m
Apr 2, 2026
NEUTRAL
4/10
Perspective Therapeutics announced that updated clinical data from its [212Pb]VMT-α-NET program for
Mar 17, 2026
MIXED
6/10
Perspective Therapeutics (CATX) reported full-year 2025 financial results and provided a clinical up
Mar 16, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 4 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.93 mean target
+326.8% upside
Strong Buy (1.27)
$6.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $3.03 |
| Target Low | $6.00 |
| Target Mean | $12.93 |
| Target Median | $13.00 |
| Target High | $18.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.45 | $-0.23 | 7.4% | -2.8% | 2↑ 1↓ | $0.0B | -68.1% | 10 |
| Next Q 2026-09-30 |
$-0.30 | $-0.52 | $-0.23 | 14.7% | -5.4% | 2↑ 0↓ | $0.0B | -55.9% | 10 |
| Current FY 2026-12-31 |
$-1.16 | $-1.37 | $-0.96 | 17.6% | +8.7% | 3↑ 1↓ | $0.0B | -53.5% | 8 |
| Next FY 2027-12-31 |
$-1.15 | $-1.39 | $-0.90 | 0.4% | +1.8% | 2↑ 2↓ | $0.0B | 16.5% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.278 | |
| 7d ago | $-0.280 | +0.002 |
| 30d ago | $-0.270 | -0.007 |
| 60d ago | $-0.270 | -0.007 |
| 90d ago | $-0.335 | +0.057 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Apr 20, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 17, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 19, 2026 | Piper Sandler | INITIATE | — | Overweight |
| Jan 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 13, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 14 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 14 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 4 | 14 | 2 | 0 | 0 | 90% | |
| Mar 1, 2026 | 4 | 14 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 4 | 13 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 4 | 13 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
short_volume
Short Volume: CATX — 58.9% short (1.0M / 1.7M)
Short: 996,517 | Exempt: 13,513 | TRF Vol: 1,690,971 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
announcement
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
<p align="justify">SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=coJJDozKV_YAf9UTfxALBE3pXa7PKP4cc
Jun 1, 2026
short_volume
Short Volume: CATX — 56.3% short (0.4M / 0.7M)
Short: 392,481 | Exempt: 460 | TRF Vol: 697,210 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: CATX — 57.0% short (0.3M / 0.6M)
Short: 316,598 | Exempt: 722 | TRF Vol: 555,487 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: CATX — 55.2% short (0.3M / 0.6M)
Short: 343,619 | Exempt: 1,474 | TRF Vol: 623,019 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
<p align="justify">SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PFLZKFTDbxa_7ghTPcnSfH1hPux0cMS9YI2
May 18, 2026
announcement
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
<p align="justify">SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=5PfWoq_8n5HrpTlAZw0K5igGMYMzo9dXr1C
May 11, 2026
announcement
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
<p align="justify">SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (N
May 11, 2026
earnings_calendar
CATX Q1 2026 Earnings Scheduled — 2026-05-11
Apr 29, 2026
short_volume
Short Volume: CATX — 63.1% short (0.3M / 0.5M)
Short: 332,099 | Exempt: 67 | TRF Vol: 526,690 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: CATX — 65.5% short (0.4M / 0.6M)
Short: 394,566 | Exempt: 9 | TRF Vol: 602,408 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
earnings_calendar
CATX Q1 2026 Earnings Scheduled — 2026-04-27
Apr 24, 2026
announcement
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
<p align="justify">SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-c4C1pPBmZHNAEkO-zFPxseB4CGpEUD-
Apr 22, 2026
short_volume
Short Volume: CATX — 56.2% short (0.3M / 0.5M)
Short: 302,202 | Exempt: 957 | TRF Vol: 537,259 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
announcement
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
<p align="justify">SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=UQcywNW-pwpn0R9UJouO4l-BG8Z27ZXRo